Checked Jun 15, 2026
How much does Mounjaro cost without insurance in 2026?
Mounjaro costs about $1,069 a month at retail without insurance. With a diabetes diagnosis and prior authorization, a covered copay runs $25 to $100 a month. Mounjaro has no direct cash program, so the cheapest tirzepatide routes are Zepbound vials from $299 a month and compounded tirzepatide from $278 a month. Here is every path and what each one really costs.
Mounjaro costs about $1,069 a monthat retail without insurance, matching Eli Lilly's published 2026 list price. With a type 2 diabetes diagnosis and prior authorization, a covered copay runs $25 to $100 a month. Mounjaro has no direct cash program, so the cheapest tirzepatide routes are Zepbound vials from $299 a month and compounded tirzepatide, the same active ingredient, from $278 a month.
- Retail price, no insurance: about $1,069 a month.Eli Lilly's published 2026 list price for the Mounjaro pen, the same at every dose. It is a sticker number, not what most people pay.
- With insurance for diabetes: $25 to $100 a month. A typical copay once a plan approves Mounjaro for type 2 diabetes. Diabetes is a long-covered indication, so this is the most common path.
- No Mounjaro cash program. Unlike Wegovy and Zepbound, Mounjaro has no manufacturer self-pay vial. For a branded tirzepatide at a cash price, the route is the Zepbound vial.
- Cheapest branded tirzepatide: $299 a month. Zepbound self-pay vials through LillyDirect, the same molecule as Mounjaro, rising to $449 a month at higher doses.
- Cheapest tirzepatide overall: $278 a month. Compounded tirzepatide at Mochi, month-to-month with no lock-in. Same active ingredient, prepared by a licensed pharmacy, supply narrowing under litigation.
- Weight loss is off-label. Mounjaro is approved for diabetes, not weight loss. For weight loss, Zepbound is the indicated tirzepatide and the simpler path.
Every tirzepatide cash path, side by side
Mounjaro is tirzepatide, made by Eli Lilly and approved for type 2 diabetes in 2022. It is the same active molecule as Zepbound at the same doses, the only difference being the approved indication. The thing that sets Mounjaro's pricing apart from Wegovy and Zepbound is what is missing: Mounjaro has no manufacturer cash program, so the cheap routes to the molecule run through Zepbound or compounding. These are ongoing prices, not multi-month prepay teasers.
| Path | Cost / mo | Cost / year | Source |
|---|---|---|---|
| Mounjaro with insurance (diabetes diagnosis) | $25 to $100 | $300 to $1,200 | Payer coverage |
| Compounded tirzepatide (same active ingredient) | $278 to $349 | $3,336 to $4,188 | Mochi $278, Price Index |
| Zepbound self-pay vials, the cheaper branded tirzepatide | $299 to $449 | $3,588 to $5,388 | Zepbound cost |
| Mounjaro pen, retail cash (no program) | about $1,069 | about $12,828 | Mounjaro drug page |
Prices are checked every Monday against Eli Lilly's published pricing, LillyDirect, and each program's published pricing, then logged on the Price Index. We do not create accounts or make purchases to verify them.
Why Mounjaro has no cash discount
Wegovy has the $149 NovoCare pill. Zepbound has the $299 LillyDirect vial. Mounjaro has neither. Eli Lilly routes its direct-to-consumer cash tirzepatide through the Zepbound name, the obesity product, not through Mounjaro, the diabetes product. So the published cash price for Mounjaro is the full retail figure of about $1,069 a month, with no manufacturer discount to bring it down.
That changes the strategy. If you have type 2 diabetes, the cheapest path is almost always insurance, because diabetes coverage is widespread. If you do not have a diabetes diagnosis, paying retail cash for Mounjaro makes little sense when the identical molecule is available as a $299 Zepbound vial or a $278 compounded preparation.
What Mounjaro costs with insurance
When a commercial plan covers Mounjaro for type 2 diabetes, the copay usually runs $25 to $100 a month. This is the cheapest path for most diabetes patients, and the easiest to clear, because diabetes is a long-standing covered indication rather than the contested weight-loss category. The hurdle is the diagnosis itself plus prior authorization, which most diabetes patients meet.
Plans rarely cover Mounjaro for weight loss alone, since Zepbound is the labeled obesity product. Check our payer coverage pages for your insurer, and if you are denied, our appeal letter builder drafts the response. Medicare Part D plans generally cover Mounjaro for diabetes; the Medicare GLP-1 cost guide covers the July 1, 2026 Bridge for the weight-loss side.
The $299 Zepbound vial: branded tirzepatide for less
If you want a branded tirzepatide at a cash price and you do not have diabetes coverage, the answer is not Mounjaro. It is Zepbound. LillyDirect sells single-dose Zepbound vials, the same tirzepatide molecule at the same doses, for $299 a month at the 2.5mg and 5mg starter doses, rising to $449 a month at higher doses. The full breakdown is on the Zepbound cost guide.
The catch is the dose. The $299 price is the two starter doses. As you titrate up the weeks of dose ramp-up before you reach your steady dose to a maintenance dose, the monthly price climbs toward $449. Treat $299 as the entry price, not the long-term price.
Compounded tirzepatide: the same molecule for $278
Compounded tirzepatide is the same active ingredient as Mounjaro, prepared for an individual patient by a licensed 503A compounding pharmacy. It is not the branded Mounjaro product and is not reviewed as a finished drug. At $278 a month it is the cheapest tirzepatide path on the chart.
The floor is $278 a month at Mochi, flat at every dose, billed month-to-month with no lock-in. Most other compounding programs land between $278 and $349. Supply has tightened sharply through 2025 and 2026 because Eli Lilly has filed coordinated lawsuits against compounded tirzepatide pharmacies, so check the live price and availability before you sign up.
What Mounjaro costs per year
Mounjaro is a long-term medication, so the annual number is the one that matters. A year of retail Mounjaro costs about $12,828 with no insurance. Compounded tirzepatide at $278 a month is about $3,336 a year, and Zepbound starter vials at $299 a month are about $3,588 a year. With insurance covering Mounjaro for diabetes, a year can cost as little as $300 to $1,200 in copays.
The gap between the cheapest tirzepatide route and retail cash is about $9,500 a year for the same molecule. That gap, plus the absence of a Mounjaro cash program, is the whole reason to compare before you start.
Why Mounjaro is so expensive in the US
The $1,069 retail price is a US phenomenon. The same tirzepatide costs a fraction of that in Europe. The US has no central drug-price negotiation, and pharmacy-benefit managers capture much of the rebate between list and net price. The retail figure is mostly a sticker. Because Mounjaro carries no cash discount, the real floor for the molecule is the $299 Zepbound vial and the $278 compounded path.
Tirzepatide earns its price on results. In the SURPASS-2 registration trial (NEJM, 2021), Mounjaro at the top dose produced a mean weight loss of 13.1% over 40 weeks in type 2 diabetes patients, beating semaglutide 1mg head to head. The clinical case is strong. The pricing case is what this page is for.
What to do next
If you have type 2 diabetes, ask your prescriber about Mounjaro and run it through insurance first, where a $25 to $100 copay is the likely outcome. If you do not have diabetes coverage and you want this molecule, do not pay $1,069 retail for Mounjaro. Compare the $299 Zepbound vial and the $278 compounded tirzepatide route instead. Read the full Mounjaro buyer's guidefor the clinical detail, compare every program's real all-in price on the GLP Chart, and see the full GLP-1 cost picture across every drug.
Mounjaro cost FAQ
How much does Mounjaro cost without insurance?
Mounjaro's retail cash price without insurance is about $1,069 a month, matching Eli Lilly's published 2026 list price. Almost no one pays a discounted cash rate, because Mounjaro has no direct-to-consumer cash program the way Wegovy and Zepbound do. The cheaper tirzepatide routes are Zepbound single-dose vials from $299 a month through LillyDirect and compounded tirzepatide, the same active ingredient, from $278 a month.
What is the cheapest way to get Mounjaro?
If you have type 2 diabetes and your plan covers it, an insured copay of $25 to $100 a month is the cheapest path. Without coverage, Mounjaro itself has no cash discount program, so the cheapest tirzepatide overall is compounded tirzepatide at $278 a month through Mochi, billed month-to-month with no lock-in. The cheapest branded tirzepatide is Zepbound self-pay vials from $299 a month through LillyDirect. Both are the same active ingredient as Mounjaro.
Does Mounjaro have a LillyDirect cash price like Zepbound?
No. LillyDirect sells single-dose tirzepatide vials under the Zepbound name for weight management, not under the Mounjaro name. There is no published LillyDirect self-pay vial for Mounjaro. If you want a branded tirzepatide at a cash price, the Zepbound vial from $299 a month is the route. Mounjaro itself is bought either through insurance with a diabetes diagnosis or at the roughly $1,069 retail cash price.
How much does Mounjaro cost per month with insurance?
When a commercial plan covers Mounjaro for type 2 diabetes, the copay typically runs $25 to $100 a month. Mounjaro is far easier to get covered than the weight-loss tirzepatide, because diabetes is a long-standing covered indication. The hurdle is the diagnosis and prior authorization. Plans rarely cover Mounjaro for weight loss alone, since Zepbound is the indicated obesity product.
Is Mounjaro the same as Zepbound?
Mounjaro and Zepbound are the same active ingredient, tirzepatide, made by Eli Lilly at the same doses. The difference is the approved indication. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. For a US patient without diabetes, Zepbound is the indicated option and has a cash-vial program; Mounjaro for weight loss is off-label and uncommon in 2026.
Is compounded tirzepatide the same as Mounjaro?
Compounded tirzepatide is the same active ingredient as Mounjaro, prepared for an individual patient by a licensed 503A compounding pharmacy. It is not the branded Mounjaro product and is not reviewed as a finished drug. It costs $278 to $349 a month cash. Supply has narrowed sharply through 2025 and 2026 because Eli Lilly has filed coordinated lawsuits against compounded tirzepatide pharmacies, so confirm the live price before you sign up.
Why is Mounjaro so expensive in the US?
Eli Lilly sets the US list price near $1,069 a month, far above the price in Europe, because the US has no central drug-price negotiation and pharmacy-benefit middlemen capture much of the rebate. The retail figure is mostly a sticker. Because Mounjaro has no cash discount program, the real cash floor for the molecule is the $299 Zepbound vial and the $278 compounded tirzepatide path.
Can I use Mounjaro for weight loss?
Mounjaro is approved for type 2 diabetes, not weight loss, and off-label Mounjaro prescribing for weight loss has narrowed sharply since Zepbound launched in late 2023. If your goal is weight loss, Zepbound is the indicated tirzepatide, the simpler insurance path, and the one with a $299 cash-vial program. The clinical effect of the molecule is the same; the label and the cash routes differ.
How much does a year of Mounjaro cost?
A year of retail-price Mounjaro costs about $12,828 with no insurance. Compounded tirzepatide at $278 a month works out to about $3,336 a year, and Zepbound starter vials at $299 a month are about $3,588 a year. With insurance covering Mounjaro for diabetes, a year can cost as little as about $300 to $1,200 in copays.
Does Medicare cover Mounjaro?
Medicare Part D plans generally cover Mounjaro for type 2 diabetes, the same as other diabetes drugs, with copays that vary by plan. Medicare does not cover Mounjaro for weight loss. From July 1, 2026, the Medicare GLP-1 Bridge is expected to offer covered GLP-1s at a flat price for qualifying Part D beneficiaries, which is the relevant program for the weight-loss indication.
